Phase I study of stereotactic body radiotherapy as postoperative adjuvant or salvage therapy for prostate cancer

Yamashita Hideomi0 个研究点目标入组 36 人开始时间: 2022年5月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•a) Patients who undergo radical prostatectomy at our hospital for prostate cancer and will receive radiation therapy as adjuvant or salvage therapy at our hospital.
•b) Performance status (PS): 0-2.
•c) Over 18 years old.
•d) Patients whose pre-registration treatment plan meets the dose constraints.
•e) A blood test within 28 days prior to the start of radiation therapy meets all of the following:
•WBC > 3,000 /mm3
•Hb > 10.0 g/dL
•Plt > 75,000 /mm3
•eGFR > 60 mL/min/1.73 m2
•f) Patients who has given written consent to participate in the study.

•a) Patients who did not consent to participate in the study.
•b) With lymph node metastasis or distant metastasis.
•c) With a history of radiation therapy to the pelvis.
•d) With inflammatory bowel disease such as ulcerative colitis and Crohn's disease.
•e) With a history of rectal surgery.
•f) Patients participating in other clinical trials that may affect the conduct or outcome of this study.
•g) Patients who are judged to be inappropriate to participate in this study by the principal investigater or co-investigaters.

发起方

Yamashita Hideomi